Show simple item record

dc.contributor.authorMay, James
dc.contributor.authorDuncan, Colin
dc.contributor.authorMol, Ben
dc.contributor.authorBhattacharya, Siladitya
dc.contributor.authorDaniels, Jane
dc.contributor.authorMiddleton, Lee
dc.contributor.authorHewitt, Catherine
dc.contributor.authorCoomarasamy, Arri
dc.contributor.authorJurkovic, Davor
dc.contributor.authorBourne, Tom
dc.contributor.authorBottomley, Cecilia
dc.contributor.authorPeace-Gadsby, Alexandra
dc.contributor.authorDoust, Ann
dc.contributor.authorTong, Stephen
dc.contributor.authorHorne, Andrew W
dc.date.accessioned2019-05-30T09:50:07Z
dc.date.available2019-05-30T09:50:07Z
dc.date.issued2018-11-20
dc.identifier.citationMay , J , Duncan , C , Mol , B , Bhattacharya , S , Daniels , J , Middleton , L , Hewitt , C , Coomarasamy , A , Jurkovic , D , Bourne , T , Bottomley , C , Peace-Gadsby , A , Doust , A , Tong , S & Horne , A W 2018 , ' A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3) : trial protocol ' , Trials , vol. 19 , 643 . https://doi.org/10.1186/s13063-018-3008-6en
dc.identifier.issn1745-6215
dc.identifier.otherPURE: 144506647
dc.identifier.otherPURE UUID: 54d678a4-fef1-4a77-988f-da78dad8d059
dc.identifier.otherPubMed: 30458863
dc.identifier.otherPubMedCentral: PMC6247635
dc.identifier.otherScopus: 85065349177
dc.identifier.urihttp://hdl.handle.net/2164/12327
dc.language.isoeng
dc.relation.ispartofTrialsen
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectAbortifacient Agents, Nonsteroidal/administration & dosageen
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectClinical Trials, Phase III as Topicen
dc.subjectDouble-Blind Methoden
dc.subjectDrug Therapy, Combinationen
dc.subjectErbB Receptors/antagonists & inhibitorsen
dc.subjectFemaleen
dc.subjectGefitinib/administration & dosageen
dc.subjectHumansen
dc.subjectMethotrexate/administration & dosageen
dc.subjectMiddle Ageden
dc.subjectMulticenter Studies as Topicen
dc.subjectPregnancyen
dc.subjectPregnancy, Tubal/diagnosisen
dc.subjectProtein Kinase Inhibitors/administration & dosageen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectTime Factorsen
dc.subjectTreatment Outcomeen
dc.subjectUnited Kingdomen
dc.subjectYoung Adulten
dc.subjectR Medicineen
dc.subjectSupplementary Dataen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRen
dc.titleA multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3) : trial protocolen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1186/s13063-018-3008-6


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record